US3903268A - Chitin and chitin derivatives for promoting wound healing - Google Patents

Chitin and chitin derivatives for promoting wound healing Download PDF

Info

Publication number
US3903268A
US3903268A US117085A US11708571A US3903268A US 3903268 A US3903268 A US 3903268A US 117085 A US117085 A US 117085A US 11708571 A US11708571 A US 11708571A US 3903268 A US3903268 A US 3903268A
Authority
US
United States
Prior art keywords
chitin
wound healing
wound
healing
fibers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US117085A
Inventor
Leslie L Balassa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lescarden Ltd
Original Assignee
Lescarden Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lescarden Ltd filed Critical Lescarden Ltd
Priority to US117085A priority Critical patent/US3903268A/en
Application granted granted Critical
Publication of US3903268A publication Critical patent/US3903268A/en
Assigned to LESCARDEN INC., reassignment LESCARDEN INC., CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). EFFECTIVE JAN. 12,1983 Assignors: LESCARDEN LTD.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives

Definitions

  • ABSTRACT Wound healing compositions and the process of healing wounds with such compositions are described, the compositions containing chitin, partially depolymerized chitin or a chitin derivative.
  • This invention relates to methods of promoting the healing of wounds and compositions therefor comprising chitin, and/or chitin derivatives and/or partially depolymerized chitin.
  • Rapid healing of wounds is particularly desired for patients in tropical countries'where the risk of infection is high. Rapid healing is also desired in the case of soldiers who have been wounded in a battle zone and cannot easily and quickly be removed therefrom. Acceleration of wound healing is highly desirable in the case of patients who cannot readily be immobilized, such as farm animals.
  • one aspect of the present invention relates to novel methodsof promoting and assisting the ;healing of wounds as, for example, damaged mammalian tissue, open ulcers, etc.,and to compositions therefor.
  • Another aspect of the invention relates to significant .improvements in wound healing strength achieved by the administration of finely divided chitin, partially depolymerized chitin or chitin derivatives to a patient.
  • An additional aspect of the present invention is concerned with articles of manufacture such as surgical bandages, surgical sutures, etc., containing the wound healing materials of the present invention.
  • Chitin is a polysaccharide, believed to be poly (N- acetylglucosamine) which forms the cell walls of fungi and the hard shell of insects and crustaceans.
  • the term chitin embraces naturally occurring chitin synthetic chitin, as well as poly (N- acetylglucosamine) and its epimer poly (N- acetylgalactosamine).
  • the N-acetylated partially depolymerized chitin e.g. chitotriose, chitobiose, is a substance which retains its polymeric nature but has undergone a reduction in molecular weight (i .e.
  • the chitin derivatives contemplated are materials such as ethers formed with pharmaceuticailyacceptable radicals and esters or salts with pharmaceutical]y-acceptable' acids.
  • suitable derivatives include hydroxy lower alkyl chitin such as hydroxyethyl chitin, carboxy alkyl chitin such as carboxymethyl chitin, salts of carboxy lower alkyl chitin such as the zinc salt, lower alkyl chitin such as methyl chitin and ethyl chitin, chitinacetate, chitin nitrate,
  • chitin citrate, chitin phosphate, N-acylderivatives derived from monocarboxylic aliphatic acids such as N- tained with the chitin materials is at least equal to and in many instances greater than that derived from the cartilage materials of theprior art.
  • the substantial immovement in rate of healing which is obtained from the use of poly (N-acetylglucosamine), i.e., chitin, ascompared to-monomeric N-acetylglucosamine is particularly surprising.
  • chitin, particularly chitin of fungal origin is a relatively uniform and easily obtained material.
  • compositions of the present invention are applied using the same techniques and processes developed for cartilage, and N-acetyl'glucosamine. Thus, it is preferred to topically apply finely divided chitin directly to the wound surface.
  • tablets, capsules or pellets of chitin may be prepared from mixtures of chitin, partially depolymerized chitin or chitin derivatives with well-known pharmaceutical excipients such as starch, sugar, certain forms of clay, etc.
  • Such tablets, capsules or pellets may be taken orally or implanted nearrthesitus pfthe wound f lter natiyely, acolloidal soleut may be prepared-fromchitin,preferably iri isb eferablyin isotonic saline solution, and
  • a poyvder orsolutioh of chitiriorof a chitin deriv a- 1 tive may also be used to impregnate a surgical gauie. 0r pad whichis applied to the wo und. Chitin may also. be
  • a Wateresoluble, d erivative of chitin may ls tered,intramu scularly, parenterally 4 ns yfiivids PhiF I -QJ?
  • n,t e iz i eim b pplied topically by blo a meterqe'd amountpfithe material onto the using a hand at'o n riiz er
  • Alternativelyfit may be applied by dusting as from a hand shaker or rna y beplac ed" together :With an inert gas under increasedpressure (i,e., above atmospheric pressure) in apressure vessel.
  • chitin frorn. such sol,tr oe ,;i necessary .to reduce the chitin in particle izetqlessghan about ⁇ 1.59 microns and preferably less QthamabOut S O rnicr ons. Due to the tough andrather fibrousnature of chitin frorn such sources, this grinding ⁇ '.is di ffiqultand ex'pen'siye Accordingly, it is preferred to use;chitin'of fungalorigin. The cell walls of fungi are .g i adf t n- 1th stoeextraot ,the
  • the finely divided chitin pr chitin optionally, with other :medicamentsas indicated, may bepackaged as a dry aerosol powder ,as described in Dutch Pa't.” application 6,415,252, published July 5, l95 this patent applijcation' is directed to a medicament for mastitis but the method of aerosol packaging described is applicable to powdered medicament haying describedp'article size) or as an aerosol foarn.
  • prqteose pep tone ,'2 gm, dextrose, 5 gml'jsodium chlojon Saboura ds broth (4Q gim, dextrose and l'O'g'm. bacride and 2.5 gm.
  • Thefflaslt's are then cooled in the oven for an additional one hour and fifteen minutes, Culture broths are remo edby filtra- Itiojn jhgough Buchh'er funnels and the growth mats distilled Water, 7 The mats are then froin and 'lyophilizedand-the dry products gr'ou'nd in a more tar witha pestle under CO jNo attempt is made to pu- .rify :the chitin. Tw e l yerpairsof rats are 'used for "each test. some inflammation is observed on all treated wounds and infection on several. The increases in ,wound healing obtainedmay be all the more significant in View of these adverse" factors.
  • 100 grams of dried fungus material (obtained from Penicillium fungus of Example 4, cultured on a BHI medium, sterilized by boiling the fungus with the medium and then filtering, washing with distilled water and drying the fungus material) is defatted by extracting the solvent-soluble fatty materials with 1000 ml. chloroform at room temperature. The chloroform is removed by filtering and then drying at reduced pressure in a vacuum desiccator.
  • the defatted fungus material is treated with 2000 ml.
  • the dried material is ground in a laboratory mortar and screened through a 400 mesh standard screen.
  • Lobster shell chitin is purified by first slurrying it in -l% aqueous NaOH for minutes at 80C, then it is washed, drained and slurried in HCl for 5 minutes at 80C, drained, slurried in water, the pH of the water adjusted to 6 with dilute aqueous NaO l-l, and finally drained and dried.
  • the dried chitin material is pulverized to a fineness of about 40 microns.
  • the material shows an average 25% increase in the wound healing over the untreated control rats.
  • a process for facilitating healing of a wound in a mammal which comprises applying as a wound healing aid at the situs of the wound a wound-healing amount of a woven fabric structure including fibers selected from the group consisting of chitin and an N-acetylated partially depolymerized chitin.
  • said wound healing aid is in the form of a bandage including chitin fibers.
  • a wound healing aid is in the form of a dressing including chitin fibers.
  • a process for facilitating healing of a wound in a mammal which comprises applying as a wound healing aid at the situs of the wound a wound-healing amount of a non-woven fabric structure including fibers selected from the group consisting of chitin ancl N- acetylated partially depolymerized chitin.
  • wound healing aid is in the form of a bandage including N-acetylated partially depolymerized chitin fibers.
  • said wound healing aid is in the form of a dressing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Wound healing compositions and the process of healing wounds with such compositions are described, the compositions containing chitin, partially depolymerized chitin or a chitin derivative.

Description

United States Patent 1191 Balassa [111 3,903,268 1 51 *Sept. 2, 1975 CHITIN AND CIIITIN DERIVATIVES FOR PROMOTING WOUND HEALING [75] Inventor: Leslie L. Balassa, Blooming Grove,
[73] Assignee: Lescarden Ltd., Goshen, NY.
[ Notice:' The portion of the tenn of this patent subsequent to Jan. 4, 1989, has been disclaimed.
22 Filed: Feb. 19, 1971 21 Appl. No.1 117,085
Related US. Application Data [60] Division of Ser. No. 704,538, Feb. I2, 1968, Pat. No.
3,632,754, and a continuation-in-part of Ser. No. 619,007, Feb. 27 1967, abandoned.-
52 us. Cl. 424/180; 424/28; 424/95; 424/154 51 Int.Cl. A6lK27/00 [58] Field of Search 424/28, 95, 180, 154
Carlozzi et al.... 424/180 Weisberg et a]. 424/330 Primary Examiner-Stanley J. Friedman Assistant ExaminerDaren M. Stephens Attorney, Agent, or Firm-Darby & Darby [57] ABSTRACT Wound healing compositions and the process of healing wounds with such compositions are described, the compositions containing chitin, partially depolymerized chitin or a chitin derivative.
9 Claims, No Drawings scribes l CHITIN AND CHITIN DERIVATIVES FOR PROMOTING WOUND HEALING This application is a division of my copending application Ser. No. 704,538 filed Feb. 12, 1968 now US. Pat. No. 3,632,754 and a continuation-in-part of copending application. Ser. No. 6l9,007 filed Feb. 27, 1967 now abandoned.
This invention relates to methods of promoting the healing of wounds and compositions therefor comprising chitin, and/or chitin derivatives and/or partially depolymerized chitin.
Medicine has long been interested in improving the H healing of wounds. Patients suffering from diabetes or undergoing extensive cortisone treatment show extremely slow rates of healing of any wounds which they receive. Thus, surgery on such patients involves additional risks not present with other patients. Moreover,
rapid healing of wounds is particularly desired for patients in tropical countries'where the risk of infection is high. Rapid healing is also desired in the case of soldiers who have been wounded in a battle zone and cannot easily and quickly be removed therefrom. Acceleration of wound healing is highly desirable in the case of patients who cannot readily be immobilized, such as farm animals.
In evaluating the utility of a material to promote wound healing, a reproducible test is necessary to give treated rat and the control rat is expressed as the percentage improvement obtained. Considering biological variance it is believed that only differences of about 10% or more are significant.
There have been several recent developments reported concerning materials which promote wound healing. in this connection US. Pat. No. 3,232,836 dethe parenteral administration of N- acetylglucosamine as a wound healing material. Utilizing the test methodof Prudden et a] referred to in the preceding paragraph, N-acetylglucosamine showed improvement in tensile strength of only about 10% whereas Prudden and his co-workers have reported significantly larger increases in wound healing by the use of cartilage preparations from various animals. Depending on the age and species of animal and the fineness of the cartilage powder, improvements ranging from to 40% in wound healing tensile strength have been reported by Prudden.
Now it has been discovered that finely divided chitin, partially depolymerized chitin, and chitin derivatives possess the ability to promote the healing of wounds.
Accordingly, one aspect of the present invention relates to novel methodsof promoting and assisting the ;healing of wounds as, for example, damaged mammalian tissue, open ulcers, etc.,and to compositions therefor.
Another aspect of the invention relates to significant .improvements in wound healing strength achieved by the administration of finely divided chitin, partially depolymerized chitin or chitin derivatives to a patient.
An additional aspect of the present invention is concerned with articles of manufacture such as surgical bandages, surgical sutures, etc., containing the wound healing materials of the present invention.
These and other aspects of the present invention will be apparent from the following description.
Chitin is a polysaccharide, believed to be poly (N- acetylglucosamine) which forms the cell walls of fungi and the hard shell of insects and crustaceans. As used herein, the term chitin embraces naturally occurring chitin synthetic chitin, as well as poly (N- acetylglucosamine) and its epimer poly (N- acetylgalactosamine). The N-acetylated partially depolymerized chitin, e.g. chitotriose, chitobiose, is a substance which retains its polymeric nature but has undergone a reduction in molecular weight (i .e. chain length) as a result of (l) enzymatic action such as by a chitinase enzyme, (2) chemical treatment such as acid hydrolysis or alkaline treatment, and (3) physical treatment. These materials are known in the art and procedures for their preparation may be found in Advances in Carbohydrate Chemistry" Vol. 15, Pages 380 to 384, Academic Press, New York 1960, the disclosure of which is incorporated herein by reference. Thus, the molecular length is in the range from 11-1 in which n corresponds to the number of repeating units in chitin to n=0 which is acetylated chitobiose.
The chitin derivatives contemplated are materials such as ethers formed with pharmaceuticailyacceptable radicals and esters or salts with pharmaceutical]y-acceptable' acids. Examples of suitable derivatives include hydroxy lower alkyl chitin such as hydroxyethyl chitin, carboxy alkyl chitin such as carboxymethyl chitin, salts of carboxy lower alkyl chitin such as the zinc salt, lower alkyl chitin such as methyl chitin and ethyl chitin, chitinacetate, chitin nitrate,
chitin citrate, chitin phosphate, N-acylderivatives derived from monocarboxylic aliphatic acids such as N- tained with the chitin materials is at least equal to and in many instances greater than that derived from the cartilage materials of theprior art. The substantial immovement in rate of healing which is obtained from the use of poly (N-acetylglucosamine), i.e., chitin, ascompared to-monomeric N-acetylglucosamine is particularly surprising. As compared to the great variability in cartilage depending on the animal, itsiage and the method of collecting the cartilage, chitin, particularly chitin of fungal origin, is a relatively uniform and easily obtained material.
The compositions of the present invention are applied using the same techniques and processes developed for cartilage, and N-acetyl'glucosamine. Thus, it is preferred to topically apply finely divided chitin directly to the wound surface. However, tablets, capsules or pellets of chitin may be prepared from mixtures of chitin, partially depolymerized chitin or chitin derivatives with well-known pharmaceutical excipients such as starch, sugar, certain forms of clay, etc. Such tablets, capsules or pellets may be taken orally or implanted nearrthesitus pfthe wound f lter natiyely, acolloidal soleut may be prepared-fromchitin,preferably iri isb eferablyin isotonic saline solution, and
A poyvder orsolutioh of chitiriorof a chitin deriv a- 1 tive mayalso be used to impregnate a surgical gauie. 0r pad whichis applied to the wo und. Chitin may also. be
a tissplv a hw k l -sh t n xantl teewun ptq fi er tonic saline, ra Wateresoluble, d erivative of chitin may ls tered,intramu scularly, parenterally 4 ns yfiivids PhiF I -QJ? it n,t e iz i eim b pplied topically by blo a meterqe'd amountpfithe material onto the using a hand at'o n riiz er Alternativelyfit may be applied by dusting as from a hand shaker or rna y beplac ed" together :With an inert gas under increasedpressure (i,e., above atmospheric pressure) in apressure vessel. In this latter means of appli and regeneratedasthe yirtually undeg raded polymer in' accordance: .y vjth tli'ei proc edures described in the prior .art by 'lihor et algPartially deace tylated chitin filaments vand fibers maybe. prepared in accordance with the procedgre described in, wisht, No. 2,040,880, These Asl v sa sly wd whe h il n $1 1 Pl injecltioniile either intramuscularly, parenterallyor ,-in,trav en9usly ,,it is first necessary to prepare adisperham 9% ,sg u en 9f h.?- ma i s; a ic l y acceptable, liquid Colloidal solutionsof chitin may be ptepa red sjng theernethod described by Lingappa and Loic lgyvqod l $9,,page 158 (1961). When adniinist redintravenously it is preferred to administer mthe cornpound in isotonie solution such as isotonic saegline, Y
Teh s i Hi0 ,jadrnixt re withgeachother, cartilage, or maybe ,co-adrninistered with other -therape u tically effective a e t wshfissss asid s r ylpelm a P rma ceut i cally aceept-able zi ncsalts-such as zinopggide,
m ne a s'z bm t nch hl te an z n e fisa at; ai isc tics such as thirnerosal and benzalkonium chloride; .zlolgal anesthetics sueh as lidogaine and procaine; antibiotics,suqlzy;as chloramphenicol, sulfanilairhide and amepi'eilline Qonjbinations ofthe therapeutically effective ,-,agents described above ohitinand/or, chitin deriya-' -ti,ve s may;b e,-,=u sed.Q I 4 f 1 ,Suitablesources of ,chitin are from lobsters, shrimp -;,.andhoth;e nustacea To. utilize. chitin frorn. such sol,tr oe ,;i necessary .to reduce the chitin in particle izetqlessghan about {1.59 microns and preferably less QthamabOut S O rnicr ons. Due to the tough andrather fibrousnature of chitin frorn such sources, this grinding {'.is di ffiqultand ex'pen'siye Accordingly, it is preferred to use;chitin'of fungalorigin. The cell walls of fungi are .g i adf t n- 1th stoeextraot ,the
v thylene oxide the, entire fungal mat pro- .s i m he .ndh iit 'ne m ri s thus substane een fonnd ,th t t -is not necessary v mn: frorn the rern l'IIIfIg CCIl material. Thus, ifdesir ed', after suitable ster'ilizationas byheat or cation, termed fae rosol application, the finely divided chitin pr chitin optionally, with other :medicamentsas indicated, may bepackaged as a dry aerosol powder ,as described in Dutch Pa't." application 6,415,252, published July 5, l95 this patent applijcation' is directed to a medicament for mastitis but the method of aerosol packaging described is applicable to powdered medicament haying describedp'article size) or as an aerosol foarn.
' 1h the following exampl thefwoundfhealing :efficiency of the yarious chitinous materials is 'deterrnined by, usingthe methdddf :Prudden et alas' de'sc'rib ed above. ln general','atlestflQ pairs of r'a'ts are used to obtain a meaningful ayera g'e for each material tested.
EXAMPLE 1 Co minercial lobster shell chitin jis grdundito a 'fine weight ratio of 1 chitin to 2 pebbles. Dry ice is then put on top of the m'ill charge and the mill is open for 5 minutes to allow the co, to; displace'thdair'in the in. The he f h rnill is then clamped 6 tight and'tl ie ig iinding'carr'idoutfdr'96 hours.Approiirnat'ely 50% r-chitindc-tiyatiyesn ay be used alone, in
;er' thepon/dered chitinipasseddthrough micron I he whole powdered chitin sci produ ced is 'the'n applied tothe 45, t es t' rats of 45 pairs of rats' 'used" in the Prudden et ai assay method described above, cent of wound healing for the treatediat's, stating the control rats as IQ( is 122%, i.e., theuse of chitin re- Various fungi are grown on either bfain-heart infusion (200 gm. calf brain, 250 beef heart, gin.
, prqteose pep tone:,'2 gm, dextrose, 5 gml'jsodium chlojon Saboura ds broth (4Q gim, dextrose and l'O'g'm. bacride and 2.5 gm. disodium phosphate) called B lll or to peptone)CaIIedQ SABT 'The cultures a r 'grown in tially neducing the po'ssibility of anallergic reaction and eliminating any interfefiejnce with the healingprocess h he ght sense b Wsh krh shallow layers of tnedia containedin flasks and held stationary until: X and extensive sporulation agents. P-riorto collectionof the growth mats, the ciiltures are killed by placing the-flasks info afcllosed oven under CO5 at-=l 2"/ C-.-'for three hours. Thefflaslt's are then cooled in the oven for an additional one hour and fifteen minutes, Culture broths are remo edby filtra- Itiojn jhgough Buchh'er funnels and the growth mats distilled Water, 7 The mats are then froin and 'lyophilizedand-the dry products gr'ou'nd in a more tar witha pestle under CO jNo attempt is made to pu- .rify :the chitin. Tw e l yerpairsof rats are 'used for "each test. some inflammation is observed on all treated wounds and infection on several. The increases in ,wound healing obtainedmay be all the more significant in View of these adverse" factors.
100 grams of dried fungus material (obtained from Penicillium fungus of Example 4, cultured on a BHI medium, sterilized by boiling the fungus with the medium and then filtering, washing with distilled water and drying the fungus material) is defatted by extracting the solvent-soluble fatty materials with 1000 ml. chloroform at room temperature. The chloroform is removed by filtering and then drying at reduced pressure in a vacuum desiccator.
The defatted fungus material is treated with 2000 ml.
1.0 N-NaOl-l solution for 18 hours at room temperature. The material is then acidified with HCl. Thereafter the material is dialyzed in distilled water until the wash water is free from chlorine ions. This procedure is repeated until a substantially purified material is obtained. The material is dried in vacuum below 50C and is a gray, friable mass.
The dried material is ground in a laboratory mortar and screened through a 400 mesh standard screen.
When the screened material is applied to 20 test rats of '20 pairs of rats there is obtained an average of about 25% increase in the wound healing of the treated rats over the untreated control rats.
EXAMPLE 7 Lobster shell chitin is purified by first slurrying it in -l% aqueous NaOH for minutes at 80C, then it is washed, drained and slurried in HCl for 5 minutes at 80C, drained, slurried in water, the pH of the water adjusted to 6 with dilute aqueous NaO l-l, and finally drained and dried.
The dried chitin material is pulverized to a fineness of about 40 microns. The material shows an average 25% increase in the wound healing over the untreated control rats.
Although the present invention has been decribed in conjunction with preferred embodiments, it is to be understood that modifications andavariations may be resorted to without departing from the spirit and scope thereof, as those skilled in the art will readily understand.
What is claimed is:
l. A process for facilitating healing of a wound in a mammal which comprises applying as a wound healing aid at the situs of the wound a wound-healing amount of a woven fabric structure including fibers selected from the group consisting of chitin and an N-acetylated partially depolymerized chitin.
2. A process according to claim 1 wherein said wound healing aid is in the form of a bandage including chitin fibers.
3. A process according to claim 1 wherein said fibers are used in the form of sutures.
4. A process according to claim 1, wherein said a wound healing aid is in the form of a dressing including chitin fibers.
5. A process according to claim 1, wherein said wound healing aid is in the form of a bandage including N-acetylated partially depolymerized chitin fibers 6. A process for facilitating healing of a wound in a mammal which comprises applying as a wound healing aid at the situs of the wound a wound-healing amount of a non-woven fabric structure including fibers selected from the group consisting of chitin ancl N- acetylated partially depolymerized chitin.
7. A process according to claim 6, wherein said wound healing aid is in the form of a bandage including N-acetylated partially depolymerized chitin fibers.
8. A process according to claim 6, wherein said wound healing aid is in the form of a dressing including

Claims (9)

1. A PROCESS FOR FACILITATING HEALING OF A WOUND IN A MAMMAL WHICH COMPRISES APPLYING AS A WOUND HEALING AID AT THE SITUS OF THE WOUND A WOUND-HEALING AMOUNT OF A WOVEN FABRIC STRUCTURE INCLUDING FIBERS SELECTED FROM THE GROUP CONSISTING OF CHITIN AND AN N-ACCTYLTED PARTIALLY DEPOLYMERIZED CHITIN.
2. A process according to claim 1 wherein said wound healing aid is in the form of a bandage including chitin fibers.
3. A process according to claim 1 wherein said fibers are used in the form of sutures.
4. A process according to claim 1, wherein said wound healing aid is in the form of a dressing including chitin fibers.
5. A process according to claim 1, wherein said wound healing aid is in the form of a bandage including N-acetylated partially depolymerized chitin fibers.
6. A process for facilitating healing of a wound in a mammal which comprises applying as a wound healing aid at the situs of the wound a wound-healing amount of a non-woven fabric structure including fibers selected from the group consisting of chitin and N-acetylated partially depolymerized chitin.
7. A process according to claim 6, wherein said wound healing aid is in the form of a bandage including N-acetylated partially depolymerized chitin fibers.
8. A process according to claim 6, wherein said wound healing aid is in the form of a dressing including chitin fibers.
9. A process according to claim 6, wherein said wound healing aid is in the form of a dressing including N-acetylated partially depolymerized chitin fibers.
US117085A 1968-02-12 1971-02-19 Chitin and chitin derivatives for promoting wound healing Expired - Lifetime US3903268A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US117085A US3903268A (en) 1968-02-12 1971-02-19 Chitin and chitin derivatives for promoting wound healing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70453868A 1968-02-12 1968-02-12
US117085A US3903268A (en) 1968-02-12 1971-02-19 Chitin and chitin derivatives for promoting wound healing

Publications (1)

Publication Number Publication Date
US3903268A true US3903268A (en) 1975-09-02

Family

ID=26814895

Family Applications (1)

Application Number Title Priority Date Filing Date
US117085A Expired - Lifetime US3903268A (en) 1968-02-12 1971-02-19 Chitin and chitin derivatives for promoting wound healing

Country Status (1)

Country Link
US (1) US3903268A (en)

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074366A (en) * 1975-03-14 1978-02-21 American Cyanamid Company Poly(N-acetyl-D-glucosamine) products
US4086335A (en) * 1975-10-29 1978-04-25 Bruscato Frank N Pharmaceutical tablets containing chitin as a disintegrant
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
US4394373A (en) * 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
EP0086627A1 (en) * 1982-02-12 1983-08-24 Unitika Ltd. Anti-cancer device
US4486416A (en) * 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
US4572906A (en) * 1983-11-21 1986-02-25 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Chitosan based wound dressing materials
US4605623A (en) * 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
EP0171254A3 (en) * 1984-08-03 1987-02-04 Unitika Ltd. Shaped chitin body
US4645757A (en) * 1979-06-21 1987-02-24 Landstingens Inkopscentral Lic Ekonomisk Forening Agent for preventing or treating infections in human beings and animals
US4857403A (en) * 1986-12-16 1989-08-15 E. I. Du Pont De Nemours And Company High strength fibers from chitin derivatives
US4861527A (en) * 1986-12-16 1989-08-29 Delucca George V High strength chitosan fibers and fabrics thereof
US4920158A (en) * 1989-10-11 1990-04-24 Medipro Sciences Limited Hydrogel-forming wound dressing or skin coating material
US4931551A (en) * 1988-07-05 1990-06-05 University Of Delaware Dispersions of chitin and product therefrom
WO1990006124A1 (en) * 1988-12-07 1990-06-14 Bentech Laboratories, Inc. Formulations for treating slow and non-healing wounds
EP0382210A1 (en) * 1989-02-08 1990-08-16 Unitika Ltd. The use of deacetylated chitin for preparing a medicament for the treatment of inflammatory skin diseases
US4956350A (en) * 1988-08-18 1990-09-11 Minnesota Mining And Manufacturing Company Wound filling compositions
US4958011A (en) * 1983-06-27 1990-09-18 Bade Maria L Ester-stabilized chitin
US4960413A (en) * 1985-11-09 1990-10-02 The Shirley Institute Wound dressing
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material
EP0477979A3 (en) * 1990-09-28 1993-03-10 Sunfibre Co.,Ltd Biological filling agent and wound-healing agent
US5308663A (en) * 1989-06-20 1994-05-03 Kanai Juyo Kogyo Company Limited Biodegradable nonwoven fabric and its molding vessel
US5405314A (en) * 1992-11-02 1995-04-11 Sunfive Company Ltd. Wound protecting member including chitin
WO1996013284A1 (en) * 1994-10-28 1996-05-09 Innovative Technologies Limited Wound treatment composition
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5905035A (en) * 1997-04-15 1999-05-18 Asahi Kasei Kogyo Kabushiki Kaisha Fungus useful for chitin production
US6117851A (en) * 1996-12-13 2000-09-12 Lescarden Inc. Treatment of osteoarthritis by administering poly-N-acetyl-D-glucosamine
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
US6174299B1 (en) 1991-09-09 2001-01-16 Harvey B. Pollard Method for treating hemophilia A and B and AIDS and devices used therein
US6444797B1 (en) 2000-07-18 2002-09-03 Ibeks Technologies Co., Ltd. Chitosan microflake and method of manufacturing the same
US20030148998A1 (en) * 2001-02-16 2003-08-07 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US6653294B2 (en) 2000-02-29 2003-11-25 Food Industry Research & Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production
US6693188B2 (en) 2001-08-08 2004-02-17 Cargill Incorporated N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine
WO2004024196A1 (en) * 2002-09-11 2004-03-25 Johnson & Johnson Medical Limited Wound dressings for the treatment of wound infection
US20040077055A1 (en) * 2001-02-16 2004-04-22 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US20050075597A1 (en) * 2003-09-12 2005-04-07 Vournakis John N. Vascular access preservation in hemodialysis patients
US20050203058A1 (en) * 2004-03-11 2005-09-15 Johnson Edwin L. Compositions of alpha- and beta-chitosan and methods of preparing them
US20050215774A1 (en) * 2002-04-02 2005-09-29 Trinkle Jamea R Chitosan production
WO2005099781A1 (en) * 2004-04-13 2005-10-27 Politechnika Lodzka (Technical University Of Lodz) A wound dressing material of dibutyrylchitin and chitin reconstituted therefrom
US20050245482A1 (en) * 2000-03-15 2005-11-03 Weiyu Fan Chitosan and method of preparing chitosan
US20060003965A1 (en) * 2002-11-01 2006-01-05 Fosdick Lawrence D N-acetyl-d-glucosamine (nag) supplemented food products and beverages
US20060058263A1 (en) * 2002-11-01 2006-03-16 Rogers Brent D Heat pasturized liquids containing glucosamine
US20060172392A1 (en) * 2001-02-16 2006-08-03 Cargill, Incorporated Water soluble beta-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US20060178344A1 (en) * 2001-02-16 2006-08-10 Cargill, Incorporated Glucosamine and N-acetylglucosamine and methods of making the same fungal biomass
US20060246114A1 (en) * 2002-11-01 2006-11-02 Rogers Brent D Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US20100228185A1 (en) * 2008-12-22 2010-09-09 Abbott Laboratories Carriers for hemostatic tract treatment
US20100227836A1 (en) * 2008-07-23 2010-09-09 The Johns Hopkins University Parenteral administration of a glucosamine
US20100323986A1 (en) * 2001-02-12 2010-12-23 Marine Polymer Technologies, Inc., Compositions and methods for modulation of vascular structure and/or function
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US20110237539A1 (en) * 2010-03-26 2011-09-29 Taiwan Textile Research Institute Spinning Solution and Method for Manufacturing Biomaterial Fibers
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US8715719B2 (en) 2010-06-16 2014-05-06 Abbott Vascular, Inc. Stable chitosan hemostatic implant and methods of manufacture
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
US9198995B2 (en) 2006-09-20 2015-12-01 Ore-Medix Llc Conformable structured therapeutic dressing
US9427397B2 (en) 2009-01-23 2016-08-30 Obagi Medical Products, Inc. Rosacea treatments and kits for performing them
US10829420B2 (en) 2016-07-22 2020-11-10 The Regents Of The University Of Colorado, A Body Corporate Filamentous organism-derived carbon-based materials, and methods of making and using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2040879A (en) * 1934-06-21 1936-05-19 Du Pont Substantially undegraded deacetylated chitin and process for producing the same
US2795579A (en) * 1953-10-09 1957-06-11 Warner Lambert Pharmaceutical Process for purification of chitosan by means of the salicylic acid salt thereof
US3232836A (en) * 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3257275A (en) * 1962-02-07 1966-06-21 Weisberg Mark Chitosan containing antacid composition and method of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2040879A (en) * 1934-06-21 1936-05-19 Du Pont Substantially undegraded deacetylated chitin and process for producing the same
US2795579A (en) * 1953-10-09 1957-06-11 Warner Lambert Pharmaceutical Process for purification of chitosan by means of the salicylic acid salt thereof
US3232836A (en) * 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3257275A (en) * 1962-02-07 1966-06-21 Weisberg Mark Chitosan containing antacid composition and method of using same

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074713A (en) * 1975-03-14 1978-02-21 American Cyanamid Company Poly(N-acetyl-D-glucosamine) products
US4074366A (en) * 1975-03-14 1978-02-21 American Cyanamid Company Poly(N-acetyl-D-glucosamine) products
US4086335A (en) * 1975-10-29 1978-04-25 Bruscato Frank N Pharmaceutical tablets containing chitin as a disintegrant
US4645757A (en) * 1979-06-21 1987-02-24 Landstingens Inkopscentral Lic Ekonomisk Forening Agent for preventing or treating infections in human beings and animals
US4486416A (en) * 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
US4394373A (en) * 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
EP0086627A1 (en) * 1982-02-12 1983-08-24 Unitika Ltd. Anti-cancer device
US4605623A (en) * 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
US4958011A (en) * 1983-06-27 1990-09-18 Bade Maria L Ester-stabilized chitin
US4572906A (en) * 1983-11-21 1986-02-25 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Chitosan based wound dressing materials
EP0171254A3 (en) * 1984-08-03 1987-02-04 Unitika Ltd. Shaped chitin body
US4960413A (en) * 1985-11-09 1990-10-02 The Shirley Institute Wound dressing
US4857403A (en) * 1986-12-16 1989-08-15 E. I. Du Pont De Nemours And Company High strength fibers from chitin derivatives
US4861527A (en) * 1986-12-16 1989-08-29 Delucca George V High strength chitosan fibers and fabrics thereof
US4931551A (en) * 1988-07-05 1990-06-05 University Of Delaware Dispersions of chitin and product therefrom
US4956350A (en) * 1988-08-18 1990-09-11 Minnesota Mining And Manufacturing Company Wound filling compositions
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material
WO1990006124A1 (en) * 1988-12-07 1990-06-14 Bentech Laboratories, Inc. Formulations for treating slow and non-healing wounds
EP0382210A1 (en) * 1989-02-08 1990-08-16 Unitika Ltd. The use of deacetylated chitin for preparing a medicament for the treatment of inflammatory skin diseases
US5308663A (en) * 1989-06-20 1994-05-03 Kanai Juyo Kogyo Company Limited Biodegradable nonwoven fabric and its molding vessel
US4920158A (en) * 1989-10-11 1990-04-24 Medipro Sciences Limited Hydrogel-forming wound dressing or skin coating material
EP0477979A3 (en) * 1990-09-28 1993-03-10 Sunfibre Co.,Ltd Biological filling agent and wound-healing agent
US6174299B1 (en) 1991-09-09 2001-01-16 Harvey B. Pollard Method for treating hemophilia A and B and AIDS and devices used therein
US5405314A (en) * 1992-11-02 1995-04-11 Sunfive Company Ltd. Wound protecting member including chitin
WO1996013284A1 (en) * 1994-10-28 1996-05-09 Innovative Technologies Limited Wound treatment composition
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US6117851A (en) * 1996-12-13 2000-09-12 Lescarden Inc. Treatment of osteoarthritis by administering poly-N-acetyl-D-glucosamine
US5905035A (en) * 1997-04-15 1999-05-18 Asahi Kasei Kogyo Kabushiki Kaisha Fungus useful for chitin production
US6653294B2 (en) 2000-02-29 2003-11-25 Food Industry Research & Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production
US7413881B2 (en) 2000-03-15 2008-08-19 Cargill, Incorporated Chitosan and method of preparing chitosan
US20050245482A1 (en) * 2000-03-15 2005-11-03 Weiyu Fan Chitosan and method of preparing chitosan
US6444797B1 (en) 2000-07-18 2002-09-03 Ibeks Technologies Co., Ltd. Chitosan microflake and method of manufacturing the same
US20100323986A1 (en) * 2001-02-12 2010-12-23 Marine Polymer Technologies, Inc., Compositions and methods for modulation of vascular structure and/or function
US8859528B2 (en) 2001-02-12 2014-10-14 Marine Polymer Technologies, Inc. Compositions and methods for modulation of vascular structure and/or function
US8481512B2 (en) 2001-02-12 2013-07-09 Marine Polymer Technologies, Inc. Compositions and methods for modulation of vascular structure and/or function
US20040077055A1 (en) * 2001-02-16 2004-04-22 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US7923437B2 (en) 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US8034925B2 (en) 2001-02-16 2011-10-11 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US7816514B2 (en) 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US8222232B2 (en) 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7049433B2 (en) 2001-02-16 2006-05-23 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US20060172392A1 (en) * 2001-02-16 2006-08-03 Cargill, Incorporated Water soluble beta-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US20060178344A1 (en) * 2001-02-16 2006-08-10 Cargill, Incorporated Glucosamine and N-acetylglucosamine and methods of making the same fungal biomass
US20030148998A1 (en) * 2001-02-16 2003-08-07 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US6693188B2 (en) 2001-08-08 2004-02-17 Cargill Incorporated N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine
US20050215774A1 (en) * 2002-04-02 2005-09-29 Trinkle Jamea R Chitosan production
US7488812B2 (en) 2002-04-02 2009-02-10 Cargill, Incorporated Chitosan production
US20090099347A1 (en) * 2002-04-02 2009-04-16 Cargill, Incorporated Chitosan production
WO2004024196A1 (en) * 2002-09-11 2004-03-25 Johnson & Johnson Medical Limited Wound dressings for the treatment of wound infection
US20060246114A1 (en) * 2002-11-01 2006-11-02 Rogers Brent D Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine
US20060058263A1 (en) * 2002-11-01 2006-03-16 Rogers Brent D Heat pasturized liquids containing glucosamine
US20060003965A1 (en) * 2002-11-01 2006-01-05 Fosdick Lawrence D N-acetyl-d-glucosamine (nag) supplemented food products and beverages
US8992453B2 (en) 2003-09-12 2015-03-31 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
US8152750B2 (en) * 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
US20050075597A1 (en) * 2003-09-12 2005-04-07 Vournakis John N. Vascular access preservation in hemodialysis patients
US20050203058A1 (en) * 2004-03-11 2005-09-15 Johnson Edwin L. Compositions of alpha- and beta-chitosan and methods of preparing them
WO2005099781A1 (en) * 2004-04-13 2005-10-27 Politechnika Lodzka (Technical University Of Lodz) A wound dressing material of dibutyrylchitin and chitin reconstituted therefrom
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US8148563B2 (en) 2006-02-03 2012-04-03 Jr Chem, Llc Chemical compositions and methods of making them
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US9198995B2 (en) 2006-09-20 2015-12-01 Ore-Medix Llc Conformable structured therapeutic dressing
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US8505730B2 (en) 2008-01-04 2013-08-13 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US20100227836A1 (en) * 2008-07-23 2010-09-09 The Johns Hopkins University Parenteral administration of a glucosamine
US8517979B2 (en) 2008-12-22 2013-08-27 Abbott Laboratories Carriers for hemostatic tract treatment
US20100228185A1 (en) * 2008-12-22 2010-09-09 Abbott Laboratories Carriers for hemostatic tract treatment
US9533076B2 (en) 2008-12-22 2017-01-03 Abbott Laboratories Carriers for hemostatic tract treatment
US9427397B2 (en) 2009-01-23 2016-08-30 Obagi Medical Products, Inc. Rosacea treatments and kits for performing them
US8389498B2 (en) 2010-03-26 2013-03-05 Taiwan Textile Research Institute Spinning solution and method for manufacturing biomaterial fibers
US20110237539A1 (en) * 2010-03-26 2011-09-29 Taiwan Textile Research Institute Spinning Solution and Method for Manufacturing Biomaterial Fibers
US8715719B2 (en) 2010-06-16 2014-05-06 Abbott Vascular, Inc. Stable chitosan hemostatic implant and methods of manufacture
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
US10829420B2 (en) 2016-07-22 2020-11-10 The Regents Of The University Of Colorado, A Body Corporate Filamentous organism-derived carbon-based materials, and methods of making and using same
US11554990B2 (en) 2016-07-22 2023-01-17 The Regents Of The University Of Colorado, A Body Corporate Filamentous organism-derived carbon-based materials, and methods of making and using same

Similar Documents

Publication Publication Date Title
US3632754A (en) Use of chitin for promoting wound healing
US3911116A (en) Process for promoting wound healing with chitin derivatives
US3914413A (en) Process for facilitating wound healing with N-acetylated partially depolymerized chitin materials
US4948540A (en) Method of preparing collagen dressing sheet material
US5622834A (en) Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
DE60307603T2 (en) CELL WALL DERIVATIVES FROM BIOMASS AND MANUFACTURE THEREOF
DE69032406T2 (en) Wound medication containing heparanase
JP3337472B2 (en) Wound healing agent
EP0138572A2 (en) Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
CN110507842B (en) Bacterial cellulose/hyaluronic acid/epsilon-polylysine functional dressing and preparation method thereof
AU2002306455A1 (en) Composition and methods for modulation of vascular structure and/or function
DE1642578B2 (en) Process for the preparation of an enzymatic composition having proteolytic enzyme and collagenase activity
US10835565B2 (en) Pharmaceutical compositions having antibacterial, antiviral, and other immunostimulatory activities
KR100315381B1 (en) Chitosan microflake and method of manufacturing them
CH628246A5 (en) METHOD FOR PRODUCING A PROTECTIVE PERTUSSIS ANTIGENT.
CN115475276A (en) Hemostatic material and wound dressing containing same
US3804949A (en) Process of promoting healing of wounds
CN117659521A (en) An extracellular polysaccharide-based hydrogel and its preparation method and application
CH639133A5 (en) METHOD FOR PRODUCING AN ANTITUMOR EFFECTIVE SUBSTANCE WITH IMMUNOSTIMULATING EFFECT.
BODEA et al. Bacterial biofilms as wound healing dressing-a review.
US20220098330A1 (en) Method for the manufacturing of chitin derivatives through treatment with ultrasounds
CN120549082A (en) Application of modified tobacco polysaccharides in the prevention of tobacco mosaic virus
RU2155812C1 (en) Biotechnological method of wound-healing preparation preparing
WO1990006124A1 (en) Formulations for treating slow and non-healing wounds
KR20250157982A (en) A Method for manufacturing microcapsules by ultrasonic treatment

Legal Events

Date Code Title Description
AS Assignment

Owner name: LESCARDEN INC.,

Free format text: CHANGE OF NAME;ASSIGNOR:LESCARDEN LTD.;REEL/FRAME:004123/0510

Effective date: 19830105

STCF Information on status: patent grant

Free format text: PATENTED FILE - (OLD CASE ADDED FOR FILE TRACKING PURPOSES)